Stay updated with breaking news from Texas liver. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article CUPERTINO, Calif., June 9, 2021 /PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall improvement from baseline observed in liver enzymes, serum lipid profiles, liver fat by imaging, and biomarkers of liver health. The poster will feature additional efficacy signal data including liver stiffness by transient elastography (TE) and magnetic resonance elastography (MRE), liver fibrosis marker, pro-C3, and ELF scores, as well as insulin resistance (HOMA-IR). ....